Mass balance, pharmacokinetics and metabolism of [14C] BMS-582664 [brivanib] prodrug of BMS-540215, in subjects with advanced or metastatic solid tumors.

Trial Profile

Mass balance, pharmacokinetics and metabolism of [14C] BMS-582664 [brivanib] prodrug of BMS-540215, in subjects with advanced or metastatic solid tumors.

Completed
Phase of Trial: Phase I

Latest Information Update: 04 Nov 2008

At a glance

  • Drugs Brivanib alaninate (Primary)
  • Indications Solid tumours
  • Focus Pharmacokinetics
  • Sponsors Bristol-Myers Squibb
  • Most Recent Events

    • 04 Nov 2008 Actual end date (Jun 2008) added as reported by ClinicalTrials.gov.
    • 04 Nov 2008 Status changed from recruiting to completed.
    • 04 Nov 2008 Actual patient number (4) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top